Home › Bleeding › Washington › Seattle
Bleeding clinical trials in Seattle, WA
5 studies for Bleeding are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- University of Washingto, Seattle
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RecruitingPhase 2
- University of Washington Harborview Medical Center, Seattle
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- University of Washingto, Seattle
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RecruitingPhase 3
- Washington Institute for Coagulation, Seattle
Hemophilia A Research Program
RecruitingObservational studyHealthy volunteers welcome
- University of Washington, Seattle
About Bleeding
Bleeding is the loss of blood, inside or outside the body. A hemorrhage is severe bleeding. Learn about the causes of bleeding and how to treat it.
More about Bleeding on MedlinePlus
Bleeding trials in other cities
- Boston, MA10 studies
- New York City, NY10 studies
- Houston, TX8 studies
- Cleveland, OH6 studies
- Los Angeles, CA6 studies
- Atlanta, GA6 studies
- Indianapolis, IN6 studies
- Chicago, IL6 studies
- Durham, NC6 studies
- St. Louis, MO5 studies
- Philadelphia, PA5 studies
- San Diego, CA5 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.